Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

Dr. Rima Jean Couzi is a cancer specialist in Towson, Maryland, caring for patients with breast cancer. Dr. Couzi earned her medical degree at the National University of Ireland. She completed residencies at St. Laurence's Hospital/Beaumont Hospitals and Galway Regional in Dublin, as well as Franklin Square Hospital in Baltimore. She performed a fellowship in medical oncology at St. Vincent's Hospital and St. James's Hospital in Dublin, and an additional fellowship in medical oncology at Johns Hopkins Oncology Center in Baltimore. She also earned a master’s degree in clinical epidemiology from the Johns Hopkins Bloomberg School of Public Health. Dr. Couzi joined the Johns Hopkins faculty in 2004. Dr. Couzi is a member of the American Society of Clinical Oncology and the Royal College of Physicians in Ireland. Selected Publications Antonarakis ES, Fradin JM, Petronis JD, Couzi RJ. “Not What It Seems.” Am J Med. 2007;120:408-411 Holdhoff M, Wung PK, Petronis J, Couzi R. “Persistent PET-positive liver lesions after successful chemotherapy in a patient with mediastinal seminoma.” J. Clin Oncol. 2007;25:2482-4. Li S, Couzi RJ, Thomas GH, Friedman AD, Borowitz MJ. “A novel variant three-way translocation of inversion 16 in a case of AML-M4eo following low dose methotrexate therapy.” Cancer Genet Cytogenet. 2001; 125:74-7. Schultz MJ, Tabb RD, Eagan JW, Citron JR, Couzi RJ. “Treating a male breast cancer patient with moderately differentiated, infiltrating ductal cancer of the breast.” Journal of Multidisciplinary Cancer Care. 2009 September – October. Siegelbaum MH, Citron JR, Eagan JW, Couzi RJ. “Treating a patient with Unfavorable-risk prostate cancer.” Journal of Multidisciplinary Cancer Care. 2009; July – August. Dr. Couzi is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Dr. Santa-Maria completed his oncology training at Johns Hopkins, and has been focused on caring for patients with breast cancer since then. He works as both a primary oncologist and consultant for patients with all types and stages of breast cancer. His research interest is in developing new types of treatment for patients with breast cancer using immunotherapy. Dr. Santa is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

Dr. Julie Lange is an assistant professor of surgery, dermatology and oncology at the Johns Hopkins University School of Medicine. Dr. Lange was one of the original members of the Johns Hopkins melanoma group when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Johns Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique. Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. She has particular interest in melanoma at extremes of age, and in the factors associated with variance in melanoma care. Dr. Lange has published the largest study of melanoma in children, adolescents and young adults. She recognizes that melanoma in the older patient is a growing epidemic and has investigated the socioeconomic, demographic and healthcare factors that influence the treatment of melanoma in older persons. Dr. Lange is a member of the melanoma panel of the National Comprehensive Cancer Network, a group that annually evaluates and revises national treatment guidelines for melanoma. In 2015, she was inducted for her work into the Miller-Coulson Academy of Clinical Excellence, which recognizes outstanding clinicians at Johns Hopkins based on a number of factors, including communication and interpersonal skills, professionalism and humanism, a scholarly approach to clinical practice, and a passion for patient care. Dr. Lange is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphadenectomy.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Dr. Armstrong works primarily in the area of women's malignancies, with a particular emphasis on breast cancer, ovarian cancer and other gynecologic malignancies, and the genetics of breast and ovarian cancer. She directs the medical gynecologic oncology clinical service and oversees therapeutic clinical trials in gynecologic cancers. Dr. Armstrong's clinical focus is on the development of new therapeutic approaches to the treatment of breast cancer and gynecologic malignancies. Particular areas of interest are intraperitoneal therapy in ovarian cancer and targeted biologic therapies. Dr. Armstrong also directs the Kimmel Cancer Center's Breast and Ovarian Cancer Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examination of new strategies for cancer screening and prevention. Dr. Armstrong has lectured locally, nationally and internationally. She is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees and as chair of several clinical trials through this group. She is a representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute. Dr. Armstrong also serves as a representative of Johns Hopkins to the National Cooperative Cancer Network serving on the ovarian cancer and breast cancer risk reduction panels. She has participated as a member of the Cancer Working Group for the Office of Research on Women's Health for the National Institutes of Health, as a scientific reviewer for the breast and ovarian cancer research programs of the Department of Defense and the National Cancer Institute, as a reviewer for the NCI Special Emphasis Panel for Insight Awards to Stamp Out Breast Cancer and as a member of the NCI SPORE Program parent committee. Dr. Armstrong also is co-principal investigator for the NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site (LAPS) at Johns Hopkins, now the major avenue for adult oncology clinical trials in the country. Recent work includes immune checkpoint inhibitor therapy in endometrial cancers with microsatellite instability and PARP inhibition in ovarian cancer. Dr. Armstrong is rated as an Experienced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, and Ovarian Cancer.

Dr. Sydney Morss Dy currently practices with the Primary Care for Cancer Survivors Program at Green Spring Station. She holds a joint appointment in medicine and in oncology at the Johns Hopkins University School of Medicine. She is a professor of health policy and management at the Johns Hopkins University Bloomberg School of Public Health. Her areas of clinical expertise include cancer survivorship, internal medicine, and palliative care. For many years, she was the physician for the pain and symptom management clinic in the Cancer Center and for Hopkins' cancer case management program. Dr. Dy earned her M.D. and her M.Sc. in health services research from the Stanford University School of Medicine. She completed both a residency and a fellowship at Johns Hopkins before joining the faculty in 2001. Dr. Dy is rated as an Experienced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Lung Cancer, Angiosarcoma, Opioid Induced Constipation, and Throat Cancer.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Michael Schultz is a General Surgeon in Towson, Maryland. Dr. Schultz is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Intraductal Papilloma, and Lymphadenectomy. Dr. Schultz is currently accepting new patients.

Lauren Schnaper is a General Surgeon in Baltimore, Maryland. Dr. Schnaper is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Intraductal Papilloma, and Mastectomy. Dr. Schnaper is currently accepting new patients.

Sankaravadivu Sivasailam is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Sivasailam is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Inflammatory Breast Cancer, and Angiosarcoma.

John Fetting is an Oncologist in Lutherville, Maryland. Dr. Fetting is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Maen Farha is a General Surgeon in Baltimore, Maryland. Dr. Farha is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Lymphadenectomy, and Colostomy. Dr. Farha is currently accepting new patients.

Takeo Fujii is an Oncologist in Baltimore, Maryland. Dr. Fujii is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, and Bone Tumor.

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Dr. Melissa Camp is the lead breast surgeon in the Johns Hopkins Kimmel Cancer Center's Breast Program at Green Spring Station. As the lead breast surgeon, Dr. Camp works closely with experts from medical oncology, radiation oncology, imaging and pathology to deliver comprehensive multidisciplinary breast cancer care to patients in a convenient community setting. Dr. Camp specializes in providing compassionate breast cancer treatment, including nipple-sparing mastectomy and breast conservation surgery, and helping newly-diagnosed patients navigate the decision-making process. She sees patients at The Johns Hopkins Hospital and at Johns Hopkins Health Care & Surgery Center - Green Spring Station. Dr. Camp received her bachelor’s degree in biochemistry/molecular biology summa cum laude from Dartmouth College. She graduated from the Johns Hopkins University School of Medicine and went on to complete residencies in general surgery and preventive medicine and to earn a master's degree in public health from the Johns Hopkins Bloomberg School of Public Health. As a member of the American Society of Breast Surgeons and the Society of Surgical Oncology, Dr. Camp has published several peer-reviewed journal articles and has presented her work at national and international medical meetings. Dr. Camp is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Subareolar Abscess, Paget Disease of the Breast, Mastectomy, and Lymphadenectomy.

Dr. Jessica Tao is a medical oncologist specializing in the care of patients with breast cancer. She co-leads the Cancer Center-wide Johns Hopkins Molecular Tumor Board, a multidisciplinary effort to interpret complex genomic information and provide individualized, precision oncology treatment recommendations to patients with all types of cancer. In addition to caring for patients, Dr. Tao maintains an active clinical-translational research program dedicated to developing novel treatments to patients with advanced cancer. Her expertise and research focuses on finding and targeting the molecular changes that drive a person’s tumor and understanding novel mechanisms of response and resistance to targeted therapies. A second major area of her research is development and application of “liquid biopsy” technologies, including circulating tumor DNA, in the early detection and disease monitoring of breast cancer. Dr. Tao is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Jennifer Joh is a General Surgeon in Lutherville, Maryland. Dr. Joh is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Lymphadenectomy, and Mastectomy. Dr. Joh is currently accepting new patients.